On June 25, the "2026 PDI Pharmaceutical R&D & Innovation Conference and Top 100 Pharmaceutical R&D List Release Ceremony" was grandly held in Chengdu. Co-guided by China Pharmaceutical University and the China Pharmaceutical Enterprise Management Association, and co-hosted by Yaozhinet and Chengdu Gao Investment Biotech Park, the event officially unveiled the "2026 China Pharmaceutical R&D Strength Ranking." ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco") was awarded two prestigious honors: inclusion in the 2026 Top 100 Comprehensive Pharmaceutical R&D Strength List and the 2026 Top 50 Biologics R&D Strength List. Recognized for its outstanding innovative R&D capabilities and robust pipeline, this dual recognition not only highlights the industry's high affirmation of ImmuneOnco's technological innovation but also further solidifies the Company's leading position in the biopharmaceutical sector.

Authoritative Rankings Unveiled: A Testament to Innovative Strength

The rankings were rigorously and objectively evaluated by the Expert Review Committee for the Pharmaceutical R&D Strength Ranking. The assessment was based on core dimensions, including scores for drug acceptance and approval in 2025, R&D investment, overall ranking metrics, clinical trial completion, and patents. The evaluation covers four major categories: the Overall List, Traditional Chinese Medicine (TCM) List, Chemical Drugs List, and Biologics List. Standing out among numerous participating enterprises, ImmuneOnco secured two major honors, demonstrating its formidable strength in comprehensive R&D and the innovative drug sector.

Solidifying the R&D Foundation: Repeatedly Validated by Authoritative Bodies

Adhering to its "Drug-by-Design" philosophy and leveraging its powerful R&D platform, ImmuneOnco has successfully built a rich pipeline comprising over ten innovative drug candidates and 12 ongoing clinical projects. This extensive portfolio, rooted in tumor immunology, not only reflects the Company's profound understanding of cutting-edge tumor biology and immunology but also underscores its exceptional expertise in efficiently translating scientific research into drug candidates.

ImmuneOnco's deep accumulation in pharmaceutical R&D is the result of long-term dedication. Historically, the Company has been selected for this authoritative ranking series multiple times in 2020, 2023, and 2025. This consistent inclusion over the years not only testifies to ImmuneOnco's sustained R&D vitality across different development stages but also demonstrates its resilience in steadily climbing the industry ranks amid market cycles, driven by a solid technological platform and efficient pipeline advancement. Securing dual spots on the 2026 lists once again marks a new milestone in the Company's comprehensive R&D strength.

Looking Ahead

Moving forward, ImmuneOnco will continue to uphold a clinical-value-driven R&D strategy. The Company will evaluate and advance candidate drug development according to phased clinical development strategies to expand their clinical applications. ImmuneOnco is committed to accelerating the clinical development and commercialization of its core pipeline, striving to unlock the therapeutic potential of its drugs, address significant unmet medical needs, and provide global patients with more breakthrough innovative therapies, thereby contributing greater strength to the Healthy China initiative.